Oncology Update: Anamorelin
Background: Cancer cachexia is a catabolic syndrome associated with uncontrolled muscle breakdown. There may be associated fat loss. Occurring in high frequency in advanced cancer, it is an indicator of poor prognosis. Besides weight loss, patients experience a cluster of symptoms including anorexia...
Main Author: | Eric Prommer |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2017-08-01
|
Series: | Palliative Care |
Online Access: | https://doi.org/10.1177/1178224217726336 |
Similar Items
-
Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
by: Graf SA, et al.
Published: (2017-08-01) -
Exploring Metabolic Pathways of Anamorelin, a Selective Agonist of the Growth Hormone Secretagogue Receptor, via Molecular Networking
by: Young Beom Kwak, et al.
Published: (2023-11-01) -
The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis
by: Jumpei Taniguchi, et al.
Published: (2023-09-01) -
Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
by: Koichi Takayama, et al.
Published: (2023-02-01) -
A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia
by: Yuri Oshima, et al.
Published: (2022-01-01)